

CENTURION®

# SilverSite®

antimicrobial access site dressing



Catheter-related infections can lead to extended hospital stays and greatly increased treatment costs. Now there's a safe, easy way to help reduce catheter-related infections: Centurion® SilverSite®. This patented dressing delivers silver **safely and directly to the catheter insertion site** to reduce bacterial colonization.

Silver is re-emerging as a preferred antimicrobial in many infection control applications. SilverSite's innovative design combines the potency of silver with the advanced delivery properties of alginate to create a natural choice for catheter site protection.

## powerful.

- Silver kills bacteria and fungi with broad spectrum activity
- Creates a zone of inhibition of up to 10mm immediately surrounding the catheter insertion site
- Inhibits Gram (-) and Gram (+) organisms, including antibiotic resistant bacteria

## long lasting.

- Delivers sustained release of antimicrobial activity for seven days
- Wicks moisture away from the site

## safe.

- Patented composition protects with silver – a proven and trusted antimicrobial
- Non-toxic, non-irritating, non-staining and latex free
- Does not adhere to site; provides comfortable wear and gentle removal


## simple.

- Extremely easy to apply
- Works instantly – no need to wet dressing to activate
- Offered in two internal diameter openings to accommodate a wide range of access devices
- Available in individual sterile packages or in customized sterile procedure kits

**SilverSite...**  
**the natural choice.**

CENTURION®

# SilverSite® antimicrobial access site dressing



For use with vascular and non-vascular percutaneous devices, including:

- Central venous catheters (CVCs)
- PICCs
- Dialysis catheters
- Peripheral IV catheters
- Epidural catheters
- Chest tubes
- Gastrostomy feeding tubes
- External fixator pins

## proven antimicrobial

*in vitro* testing demonstrates SilverSite's effectiveness in inhibiting the growth of the following pathogens:

MRSA – Methicillin-resistant  
*Staphylococcus aureus*

VRE – Vancomycin-resistant  
*Enterococcus*

*Escherichia coli*

*Staphylococcus aureus*

*Pseudomonas aeruginosa*

*Candida albicans*

All findings are based on results of *in vitro* testing.

US Patent No. 6,696,077

Other US Patents Issued and Pending



The National Company with the Regional Name™  
Headquarters: Howell, MI 48843 • USA • (800) 248-4058 • [www.tshsc.com](http://www.tshsc.com)